Arvinas unveils clinical data for experimental LRRK2 degrader

Arvinas unveils clinical data for experimental LRRK2 degrader
Arvinas reveals PROTAC LRRK2 data

Arvinas announced plans to share new data in an oral presentation on its PROTAC LRRK2 degrader at an upcoming movement disorder event.

The company did not provide specific details in the tweet but indicated that more information would be disclosed during the oral presentation. The development relates to therapies for conditions such as Parkinson disease, emphasizing Arvinas ongoing commitment to advancing its pipeline of targeted protein degraders.

Arvinas has recently expanded its research into targeted protein degradation. The company started dosing in a Phase 1/2 clinical trial of its HPK1 PROTAC degrader, marking an early step in developing new therapies for challenging diseases, according to a previous report here. The ongoing studies highlight Arvinas’s efforts to advance its clinical pipeline.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.